相关实验视频
Updated: Jun 7, 2025

04:45
Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
Published on: June 2, 2022
2.2K
过化是否能在所有重症患者中弥补功能性阿尔法1-抗素 (A1AT) 缺陷?
Malika Balduyck1, Sarah Afif2, Brigitte Onraed3
1Laboratoire de Biochimie « Hormonologie, Métabolisme, Nutrition & Oncologie », CHU, F-59037 Lille, France; Univ. Lille ULR 7364-RADEME, F-59000 Lille, France.
Biochimie
|November 18, 2024
概括
功能性α-1抗素 (A1AT) 缺乏症在非COVID-19重症监护室患者和不良结果患者中更为常见. 非COVID-19患者试图通过增加A1AT来弥补缺陷.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 关键护理医学 关键护理医学
背景情况:
- 阿尔法-1抗素 (A1AT) 是一个关键的蛋白酶抑制剂.
- 过化糖形式 (HSG) 增强了A1AT的保护功能.
- 不同的ICU人群中A1AT缺乏和HSG的患病率和影响在很大程度上是未知的.
研究的目的:
- 为了调查A1AT功能缺陷和HSG在重症监护室 (ICU) 患者的发生,各种原因的入院.
- 确定这些因素与患者的治疗结果有关的预后意义.
主要方法:
- 分析了248名ICU患者 (173名COVID-19,75名非COVID-19) 的血清样本.
- 通过测量相对于计算EIC的弹性酶抑制能力 (EIC) 来评估功能性A1AT缺乏.
- 用同电聚焦和凝密度计来确定和量化HSG.
主要成果:
- 在非COVID-19 (18.7%) 与COVID-19 (6.9%) 密切护理室患者中,功能性A1AT缺乏症的发生率是非COVID-19 (18.7%) 的3倍.
- 功能性缺陷在COVID-19队列中的死者比活患者更为普遍.
- 在已故的非COVID-19患者中,M1 HSG的比例增加,这表明存在补偿机制.
结论:
- 功能性A1AT缺乏症在非COVID-19ICU患者和不良结果患者中更为常见.
- 患有非COVID-19相关的ICU入院和不良预后的患者可能会尝试通过增加M1 HSG比例来补偿A1AT缺乏.
相关概念视频
Acute Respiratory Failure-III
159
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
159
Acute Respiratory Failure-V
123
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123
Acute Respiratory Failure-II
174
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
174
Acute Respiratory Failure-I
175
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
175
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
175
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
175

